[Alloimmunization and transfusion refractoriness to thrombocyte substitution].
No generally accepted policy for avoiding HLA-alloimmunization has so far been established. However, several studies suggest that single-donor instead of random-donor transfusions, white cell depletion, UV-radiation of blood products or application of cyclosporine to the recipient may avoid or at least delay alloimmunization. With regard to cost effectiveness, it would be essential to identify patients with the highest risk of developing alloimmunization. For the time being, transfusion of crossmatch-compatible HLA-selected single donor platelets should be restricted to alloimmunized patients, refractory to pooled random donor platelets.
Söhngen
D
D
Medizinische Klinik und Poliklinik der Heinrich-Heine Universität Düsseldorf.
Schneider
W
W
D016913:Blood Component Transfusion; D001787:Blood Group Incompatibility / Q000276:immunology* / Q000517:prevention & control; D001788:Blood Grouping and Crossmatching; D001792:Blood Platelets / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D007519:Isoantigens / Q000276:immunology*
D015395:Histocompatibility Antigens Class I; D007519:Isoantigens
Alloimmunisierung und Transfusionsrefraktärität bei Thrombozytensubstitution.